Mesenchymal stromal cells moving forward

Same author

Experience and uncertainty analysis of CT-based adaptive radiotherapy for abdominal treatments.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)·2025

Same author

Causes of death among cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Same author

Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment.

Brachytherapy·2014

Same author

Seminal Vesicle Target Delineation for Intermediate-Risk Prostate Cancer IMRT.

Practical radiation oncology·2014

Same author

A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up.

Bone marrow transplantation·2012

Same author

Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.

Leukemia·2009

Same journal

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Cytotherapy·2026

Same journal

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Cytotherapy·2026

Same journal

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Cytotherapy·2026

Same journal

Manufacturing strategies for prolonged CAR-T cell persistence.

Cytotherapy·2026

Same journal

Overcoming five main challenges to targeting hematologic malignancies.

Cytotherapy·2026

Same journal

Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.

Cytotherapy·2026

Related Experiment Videos

Mesenchymal stromal cells moving forward

Related Concept Videos

Experience and uncertainty analysis of CT-based adaptive radiotherapy for abdominal treatments.

Causes of death among cancer patients.

Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment.

Seminal Vesicle Target Delineation for Intermediate-Risk Prostate Cancer IMRT.

A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up.

Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Manufacturing strategies for prolonged CAR-T cell persistence.

Overcoming five main challenges to targeting hematologic malignancies.

Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.

Related Experiment Videos

Mesenchymal stromal cells moving forward

Related Concept Videos

Related Articles

Experience and uncertainty analysis of CT-based adaptive radiotherapy for abdominal treatments.

Causes of death among cancer patients.

Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment.

Seminal Vesicle Target Delineation for Intermediate-Risk Prostate Cancer IMRT.

A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-up.

Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Manufacturing strategies for prolonged CAR-T cell persistence.

Overcoming five main challenges to targeting hematologic malignancies.

Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.